Corcept Therapeutics | CORT - Equity Capital And Reserves



Corcept Therapeutics reported $635.79M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Alaunos Therapeutics USD 2.06M 661K Dec/2024
ANI Pharmaceuticals USD 436.76M 18.14M Jun/2025
Ardelyx USD 139.53M 33.76M Jun/2025
Aurora Cannabis CAD 588.68M 15.76M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Canopy Growth CAD 488.98M 102.49M Jun/2025
Corcept Therapeutics USD 635.79M 47.49M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Knight Therapeutics CAD 773.91M 11.11M Sep/2024
Merck USD 49.06B 725M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Novartis USD 42.05B 1.99B Jun/2025
Pacira USD 757.77M 40.77M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Supernus Pharmaceuticals USD 1.06B 33.2M Jun/2025
TG Therapeutics USD 276.43M 39.14M Jun/2025